Navigation Links
Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company

SAN DIEGO, Oct. 21, 2011 /PRNewswire/ -- Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by certain officers and directors at KV Pharmaceutical Company (NYSE: KV-A, KV-B).


Robbins Umeda LLP's investigation focuses on whether officials at KV Pharmaceuticals breached their fiduciary duties to shareholders, maintained woefully inadequate controls, and wasted corporate assets to the detriment of the company and investors.  In particular, the firm is investigating allegations that officials at the company caused KV Pharmaceuticals to misrepresent the extent of expanded patent access granted by the U.S. Food and Drug Administration (the "FDA") for its Makena product line.  After gaining FDA approval, officials at the company made the decision to increase the price of Makena by over 1490% to $1,500.  

On March 17, 2011, two United Stated Senators sent a letter to the Federal Trade Commission stating that "KV Pharmaceuticals actions will result in diminished access to appropriate healthcare for women and result in increased preterm birth." Additionally, on March 30, 2011, the FDA issued a statement that it would not take enforcement action against companies that manufactured compound or generic versions of Makena.

Since these facts have emerged, KV Pharmaceuticals has been forced to lower the price of its Makena product line.  In addition, the company is increasingly the subject of costly public and legal scrutiny.  These events have apparently taken its toll on KV Pharmaceutical's stock price.  After recently trading as high as $13.07 per share on March 8, 2011, shares of KV Pharmaceuticals closed on October 19, 2011, at just $1.39 per share.  

If you own shares of KV Pharmaceuticals and would like more information about your rights, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or via the shareholder information form on our website.  

Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. The law firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career shareholder rights attorneys. For more information, please go to

Press release link:

Attorney Advertising.

SOURCE Robbins Umeda LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Robbins & Myers Announces Regular Quarterly Cash Dividend
2. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
3. Robbins & Myers To Release First Quarter Fiscal 2010 Financial Results
4. Robbins & Myers to Release Second Quarter Fiscal 2010 Financial Results
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Robbins & Myers to Present at KeyBanc Capital Markets Conference
7. Robbins & Myers to Present at Bairds 2010 Industrial Conference November 9, 2010
8. Robbins Geller Rudman & Dowd LLP Announces Notice of Hearing to Determine Approval of Proposed Settlement of Class Action
9. Robbins & Myers to Release Financial Results for Second Quarter Fiscal 2011
10. Robbins & Myers Completes Sale of Romaco Businesses
11. Robbins & Myers Announces Regular Quarterly Cash Dividend
Post Your Comments:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
(Date:6/24/2016)... Arizona (PRWEB) , ... June 24, 2016 , ... ... practice, is supporting the upcoming 2016 Miss Arizona pageant as its official Medspa ... serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the ...
Breaking Medicine News(10 mins):